Healthcare / Medical Instruments & SuppliesTaipei Exchange
$30.05
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $128.0M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
63/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
11.0x
↓EV/EBITDA
5.0x
↓ROE
11.9%
↑Gross Margin
39.5%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.4%
FCF CAGR
+18.2%
FCF margin
13.1%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.38B · net income $164.3M · FCF $180.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.38B | $1.38B | $1.17B | $1.06B | $1.14B |
| Net Income | $164.3M | $164.3M | $110.6M | $68.7M | $154.0M |
| EBITDA | $281.6M | $281.6M | $205.7M | $150.8M | $236.7M |
| EPS | — | — | 1.84 | 1.20 | 2.69 |
| Gross Margin | 39.5% | 39.5% | 34.1% | 32.3% | 37.0% |
| Operating Margin | 14.5% | 14.5% | 8.5% | 5.8% | 13.5% |
| Net Margin | 11.9% | 11.9% | 9.5% | 6.5% | 13.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.15 | 0.24 | 0.24 |
| Current Ratio | 2.26 | 2.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $180.1M | $180.1M | $128.0M | $-27.5M | $109.0M |
| Returns | |||||
| ROE | 11.9% | 11.9% | 8.7% | 5.6% | 12.6% |
| Valuation | |||||
| P/E | 11.05 | 11.05 | 14.57 | 20.91 | 9.36 |
| EV/EBITDA | 4.98 | 4.98 | 7.11 | 8.93 | 5.40 |
| P/B | 1.30 | 1.30 | 1.27 | 1.18 | 1.18 |
| Growth & Yield | |||||
| Revenue Growth | 18.1% | 18.1% | 9.9% | -7.2% | — |
| EPS Growth | — | — | 53.3% | -55.4% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.3%
Start / end P/E
n/dx → n/dx
EPS bridge
1.84 → n/d
Residual
+1.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.